Provided by Tiger Trade Technology Pte. Ltd.

TYK MEDICINES-B

3.515
-0.215-5.76%
Volume:2.63M
Turnover:9.24M
Market Cap:1.34B
PE:-3.76
High:3.760
Open:3.760
Low:3.350
Close:3.730
52wk High:22.560
52wk Low:2.410
Shares:380.07M
HK Float Shares:375.46M
Volume Ratio:0.33
T/O Rate:0.70%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.936
ROE:-70.66%
ROA:-28.19%
PB:4.38
PE(LYR):-3.76
PS:10675.84

Loading ...

Strategic Collaboration Sees Qilu Invest RMB 400 Million in TYK MEDICINES-B for TY-9591 Development and Commercialization

Stock News
·
Jul 21

TYK Medicines Prices Private Placement of 63,222,744 H Shares at HK$ 7.3 Each

Reuters
·
Jul 21

Tyk Medicines - to Receive Aggregate Upfront Payment of Rmb700 Mln Plus Potential Milestone Payments

THOMSON REUTERS
·
Jul 21

Tyk Medicines - Co Enters License and Collaboration Agreement with Qilu for Ty-9591 in China

THOMSON REUTERS
·
Jul 21

Hong Kong Shares Surge: TYK MEDICINES-B Soars Over 15% in Afternoon Trading on Key Drug Trial Results

Stock News
·
Jul 21

TYK MEDICINES-B Shares Surge Over 15% on Upcoming Commercialization of TY-9591 and Positive Clinical Data for Edotinib

Stock News
·
Jul 14

TYK MEDICINES-B Shares Surge Over 6% on Positive Clinical Data for Brain Metastasis Drug, Anticipated Q3 Launch

Stock News
·
Jul 08

TYK Medicines Convenes 15 July 2026 EGM to Secure Share-Issuance Mandate

Bulletin Express
·
Jun 29

TYK Medicines Seeks Shareholders’ Approval for 20% General Share Issuance Mandate

Bulletin Express
·
Jun 29

TYK Medicines Announces Extraordinary General Meeting

Reuters
·
Jun 29

TYK Medicines Sets 10–15 July 2026 Book Closure to Determine EGM Voting Entitlements

Bulletin Express
·
Jun 24

TYK Medicines shareholders pass Articles of Association amendments at AGM

Reuters
·
Jun 23

TYK Medicines Keeps Share Capital Steady at 380.07 Million H Shares in May; Public Float Meets 25% Rule

Bulletin Express
·
Jun 02

Major Breakthrough at ASCO 2026: TYK MEDICINES-B's Edotinib Achieves 95.5% Intracranial Objective Response Rate, Leading the Frontline Treatment for EGFR Lung Cancer Brain Metastases

Stock News
·
Jun 01

TYK Medicines reports superior interim Phase II data for asandeutertinib versus osimertinib in first-line EGFR-mutant NSCLC with brain metastases

Bulletin Express
·
May 31

Key Phase II ESAONA Study Results for TYK MEDICINES-B's (02410) TY-9591 in First-Line NSCLC Brain Metastases Presented as Late-Breaking Abstract at 2026 ASCO

Stock News
·
May 31

TYK Medicines says Phase II study shows asandeutertinib beats osimertinib on intracranial response in EGFR-mutant NSCLC with brain metastases

Reuters
·
May 31

TYK Medicines Releases 2025 AGM Agenda Covering Profit Distribution, Share Mandates and Board Re-election

Bulletin Express
·
May 22

TYK Medicines to Seek 20% Share Issue Mandate, RMB300 Million Bank Lines and No-Dividend Plan at 23 June AGM

Bulletin Express
·
May 22

Insiders Could Have Profited By Holding onto TYK Medicines Shares Despite 12% Drop

Simply Wall St.
·
May 14